Halcinonide in the treatment of corticosteroid responsive dermatoses.
D000287:Administration, Topical; D000293:Adolescent; D000328:Adult; D000368:Aged; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D001623:Betamethasone / Q000627:therapeutic use; D002648:Child; D002986:Clinical Trials as Topic; D003876:Dermatitis, Atopic / Q000188:drug therapy; D004485:Eczema / Q000188:drug therapy; D004487:Edema / Q000188:drug therapy; D004890:Erythema / Q000188:drug therapy; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009450:Neurodermatitis / Q000188:drug therapy; D010146:Pain / Q000188:drug therapy; D014677:Pharmaceutical Vehicles; D011282:Pregnenediones / Q000627:therapeutic use*; D011537:Pruritus / Q000188:drug therapy; D011565:Psoriasis / Q000188:drug therapy; D012871:Skin Diseases / Q000188:drug therapy*; D013258:Steroids, Chlorinated / Q000627:therapeutic use; D013259:Steroids, Fluorinated / Q000627:therapeutic use; D013329:Structure-Activity Relationship; D014222:Triamcinolone Acetonide
D000893:Anti-Inflammatory Agents; D014677:Pharmaceutical Vehicles; D011282:Pregnenediones; D013258:Steroids, Chlorinated; D013259:Steroids, Fluorinated; D001623:Betamethasone; D014222:Triamcinolone Acetonide